ES2060778T3 - Igf-1 o-glicosilado. - Google Patents

Igf-1 o-glicosilado.

Info

Publication number
ES2060778T3
ES2060778T3 ES89308348T ES89308348T ES2060778T3 ES 2060778 T3 ES2060778 T3 ES 2060778T3 ES 89308348 T ES89308348 T ES 89308348T ES 89308348 T ES89308348 T ES 89308348T ES 2060778 T3 ES2060778 T3 ES 2060778T3
Authority
ES
Spain
Prior art keywords
igf
glycosilated
glycosylated
analog
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89308348T
Other languages
English (en)
Inventor
Anna Dr Skottner-Lundin
Linda Dr Fryklund
Par Dr Gellerfors
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Application granted granted Critical
Publication of ES2060778T3 publication Critical patent/ES2060778T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN O-GLICOSILATADO ANALOGO AL IGF-1 HUMANO EL CUAL PUEDE SER EXPRESADO JUNTO CON UN IGF-1 GLICOSILATADO POR CELULAS DE LEVADURA. UNA COMPOSICION FARMACEUTICA CONTIENE IGF-1 GLICOSILATADO, Y UN METODO PARA OBTENER IGF-1 O-GLICOSILATADO.
ES89308348T 1988-08-20 1989-08-17 Igf-1 o-glicosilado. Expired - Lifetime ES2060778T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888819826A GB8819826D0 (en) 1988-08-20 1988-08-20 Glycosylated igf-1

Publications (1)

Publication Number Publication Date
ES2060778T3 true ES2060778T3 (es) 1994-12-01

Family

ID=10642464

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89308348T Expired - Lifetime ES2060778T3 (es) 1988-08-20 1989-08-17 Igf-1 o-glicosilado.

Country Status (15)

Country Link
US (1) US5273966A (es)
EP (2) EP0429502A1 (es)
JP (1) JP2543998B2 (es)
AT (1) ATE109206T1 (es)
AU (1) AU623675B2 (es)
CA (1) CA1335802C (es)
DE (1) DE68917061T2 (es)
DK (1) DK175360B1 (es)
ES (1) ES2060778T3 (es)
FI (1) FI102282B (es)
GB (1) GB8819826D0 (es)
IE (1) IE65096B1 (es)
NO (1) NO180636C (es)
NZ (1) NZ230383A (es)
WO (1) WO1990002198A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5231178A (en) * 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
JPH06506117A (ja) * 1991-04-01 1994-07-14 メルク　エンド　カンパニー　インコーポレーテッド ピキア（Ｐｉｃｈｉａ）蛋白質分解活性に影響する遺伝子およびその使用
SG46612A1 (en) * 1992-12-02 1998-02-20 Hoechst Ag Process for obtaining proinsulin in processing correctly linked cystine bridges
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8343918B2 (en) * 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides
US20120213728A1 (en) * 2009-10-30 2012-08-23 Merck Granulocyte-colony stimulating factor produced in glycoengineered pichia pastoris
US20100172865A1 (en) * 2010-03-18 2010-07-08 Shantha Totada R Methods of enhancing hair growth
ES2674567T3 (es) 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Proteínas de fusión biespecíficas
BR112016005716A2 (pt) 2013-10-02 2017-09-12 Nat Institutes Of Health miméticos de fator de crescimento semelhante à insulina para uso em terapia
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486216T2 (de) * 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.

Also Published As

Publication number Publication date
NO180636C (no) 1997-05-21
DK29491A (da) 1991-04-19
NO910669D0 (no) 1991-02-19
DE68917061T2 (de) 1994-11-17
DK29491D0 (da) 1991-02-20
EP0360411B1 (en) 1994-07-27
NO180636B (no) 1997-02-10
EP0360411A1 (en) 1990-03-28
FI910795A0 (fi) 1991-02-19
FI102282B1 (fi) 1998-11-13
CA1335802C (en) 1995-06-06
WO1990002198A1 (en) 1990-03-08
ATE109206T1 (de) 1994-08-15
JP2543998B2 (ja) 1996-10-16
AU4051889A (en) 1990-03-23
EP0429502A1 (en) 1991-06-05
FI102282B (fi) 1998-11-13
NO910669L (no) 1991-02-19
NZ230383A (en) 1992-01-29
JPH05505514A (ja) 1993-08-19
DE68917061D1 (de) 1994-09-01
IE65096B1 (en) 1995-10-04
AU623675B2 (en) 1992-05-21
IE892652L (en) 1990-02-20
US5273966A (en) 1993-12-28
GB8819826D0 (en) 1988-09-21
DK175360B1 (da) 2004-09-13

Similar Documents

Publication Publication Date Title
ES2129423T3 (es) Vacunas.
IT8820474A0 (it) Turbopropulsore ad eliche propfan.
FI894888A7 (fi) Astaksantiinia tuottavia hiivasoluja, menetelmiä niiden valmistamiseks i ja niiden käyttö
IT8522521A0 (it) Lavoro, con porzioni separate. sedia, in particolare sedia da
DK0721343T3 (da) Farmaceutiske formuleringer omfattende en nervevækstfaktor
DE68907483D1 (de) Vitamin d analoge.
AU7082887A (en) Method of stimulating melanocytes by topical application of analogs of alpha-msh, and compositions for use in same
IT8422917A0 (it) Procedimento e forno a tunnel per la calcinazione di corpi carboniosi, in particolare di elettrodi.
IT1206730B (it) Amidi ed esteri di diidropiridinildicarbossilato farmaceuticamente utili.
AU4051889A (en) 0-glycosylated igf-1
IT8621393A0 (it) Composizioni farmaceutiche ad azione vasodilatatrice e dantianossica.
DE58906338D1 (de) Kombination von Angiotensin-Converting-Enzyme-Hemmern mit Kaliumkanal-Modulatoren sowie deren Verwendung in Arzneimitteln.
EP0330367A3 (en) Digital to analogue convertors
IT1230505B (it) Procedimento per la conversione della daunorubicina in doxorubicina.
IT7922818A0 (it) Procedimento per mantenere attiva la cultura di fermenti.
IT8921837A0 (it) Composizione di combustibile ad elevato contenuto energetico, contenete quadriciclano.
FI885425A7 (fi) Justerbar stol.
SE8204871L (sv) Farmaceutiska preparat, innefattande humant proinsulin
IT8822296A0 (it) Composizione di combustibile ad elevato contenuto energetico.
IT7924358A0 (it) Antibiotici, procedimento per laloro preparazione, e coltura biologicamente pura per impiego in tale procedimento.
ES2020176B3 (es) Composicion de apresto de alcohol polivinilico de actividad elevada en tejidos, poco espumosa.
SU523513A1 (ru) Лини задержки
IT8523123V0 (it) Struttura di seggiola, trasformabile in panchina.
ES8801763A1 (es) Procedimiento para la fabricacion industrial de galletas rellenas.
GR3007479T3 (es)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 360411

Country of ref document: ES